Welcome to our dedicated page for Clearpoint Neuro news (Ticker: CLPT), a resource for investors and traders seeking the latest updates and insights on Clearpoint Neuro stock.
ClearPoint Neuro, Inc. (symbol: CLPT) is a leading medical device company based in the United States, specializing in the development and commercialization of innovative platforms designed for performing minimally invasive surgical procedures in both the brain and heart, utilizing magnetic resonance imaging (MRI) guidance. Since its inception in 1998, ClearPoint Neuro has been at the forefront of interventional MRI research and product development.
The company's flagship product, the ClearPoint® System, is currently being used in the United States for minimally invasive brain surgeries. This system allows for precision and real-time visualization during complex neurosurgical procedures, significantly improving patient outcomes. The ClearTrace® System, still under development, aims to bring similar advancements to cardiac surgeries, offering minimally invasive solutions for heart procedures.
ClearPoint Neuro's product portfolio includes the ClearPoint System, ClearPoint Services, and ClearPoint Therapeutic Solutions. Their latest innovation, the Prism Neuro Laser Therapy System, received FDA clearance and has been integrated with the company's SmartFrame Array® 1.2 software, enhancing the practicality and efficiency of neuro laser therapies. This integration allows for combined biopsy and laser therapy procedures to be performed in a single setting, reducing setup times and improving procedural accuracy.
Financially, ClearPoint Neuro has shown robust growth. In the fourth quarter of 2023, the company reported a record revenue of $6.8 million, marking a 30% increase. Their strategic partnerships, including those with clinical and pharmaceutical firms, further bolster their financial stability and market reach. The recent equity offering of approximately $15 million has solidified their balance sheet, reinforcing investor confidence in their continued growth and innovation.
ClearPoint Neuro is also deeply involved in advancing gene and cell therapy. Their SmartFlow® Cannula is a key device used globally for delivering approved gene therapies directly to the brain. This device has been instrumental in numerous clinical trials, including those for treating AADC deficiency and Frontotemporal Dementia (FTD).
Overall, ClearPoint Neuro remains committed to driving innovation in the medical field, with a strong focus on improving surgical outcomes through advanced imaging and precise navigation technologies. For more information, visit their website at www.clearpointneuro.com.
ClearPoint Neuro, Inc. (Nasdaq: CLPT) announced a strategic partnership with adeor medical AG to distribute the Velocity Alpha high-speed surgical drill system in the U.S. This FDA-cleared product will enhance ClearPoint’s offerings for neurosurgeons in cranial and spinal procedures. The partnership also includes developing an MRI conditional version of the drill, allowing exclusive global distribution rights to ClearPoint. The U.S. market for powered drill solutions is valued at approximately $200 million, with the cranial and spine market exceeding $50 million.
ClearPoint Neuro announced the installation of its Neuro Navigation System at Hôpital Fondation Rothschild in Paris, enhancing pediatric neurosurgery through intra-procedural MRI guidance. This collaboration aims to streamline laser interstitial thermal ablations, allowing for procedures to be conducted entirely within the MRI suite. Matt Rabon emphasized the strategic move to establish additional trial centers in Europe, the UK, and the Middle East, facilitating partnerships with pharmaceutical companies. ClearPoint has FDA clearance, is CE-marked, and is active in over 60 sites globally.
ClearPoint Neuro, Inc. (Nasdaq: CLPT) will announce its 2021 second-quarter financial results on August 10, 2021, after market close. A live broadcast will take place on the same day at 4:30 p.m. Eastern time. Those unable to attend can access a replay until September 10, 2021. The Company focuses on enabling therapies for neurological disorders via its ClearPoint Neuro Navigation System, which has FDA clearance and is deployed in over 60 active sites globally. The Company has partnered with over 30 pharmaceutical firms and has conducted more than 4,500 cases to date.
ClearPoint Neuro (Nasdaq: CLPT) and Blackrock Neurotech have formed a joint agreement to develop an automated surgical solution for implanting Brain Computer Interfaces (BCIs) targeting various neurological disorders. This collaboration aims to enhance surgical efficiency and predictability in BCI implantation using ClearPoint's advanced navigation platform. The growing market for BCIs and neuro-navigational systems is estimated to exceed $1 billion annually. Blackrock will partially fund development efforts, seeking to commercialize rapid, automated procedures for improved patient outcomes.
ClearPoint Neuro, Inc. (Nasdaq: CLPT) announced the appointment of Lynnette C. Fallon to its Board of Directors effective immediately. Fallon, currently Executive VP and General Counsel at Axcelis Technologies, brings over two decades of experience in business development, financial management, and corporate compliance. President and CEO Joe Burnett expressed optimism about her contributions to human resources and investor relations. ClearPoint Neuro aims to improve treatments for neurological disorders with its FDA-cleared ClearPoint Navigation System, which is operational in over 60 sites worldwide.
ClearPoint Neuro, Inc. (Nasdaq: CLPT) announced the installation of its version 2.0 software at Mazowiecki Szpital Bródnowski in Warsaw, Poland. This milestone allows for advanced procedures including deep brain stimulation, biopsies, and clinical trials. Professor Mirosław Ząbek praised the ClearPoint team's dedication during installation, anticipating significant clinical advancements. Matt Rabon emphasized the importance of Poland's clinical trial market and the ongoing strategy to expand ClearPoint’s drug delivery trial centers in Europe as COVID-19 restrictions ease.
ClearPoint Neuro, Inc. (Nasdaq: CLPT) will join the Russell 3000 Index effective June 28, 2021. This addition, announced in a preliminary list on June 4, will enhance the company's institutional shareholder base and visibility among investors. The Russell 3000 Index includes the largest U.S. stocks by market capitalization, facilitating investment strategies for a significant number of fund managers. ClearPoint Neuro develops advanced navigation and delivery systems for complex neurological therapies, with FDA-approved products currently operating at over 60 sites globally.
ClearPoint Neuro has achieved a significant milestone by treating the first patient using its platform in a Phase 1 clinical trial for advanced Parkinson's disease. Conducted by BlueRock Therapeutics, this trial investigates the safety and efficacy of pluripotent stem cell-derived dopaminergic neurons. The surgery was performed at Memorial Sloan Kettering Cancer Center, utilizing the ClearPoint Neuro Navigation System. This trial aims to enroll ten patients across sites in the U.S. and Canada, highlighting ClearPoint's role in advancing treatments for complex neurological conditions.
ClearPoint Neuro (Nasdaq: CLPT) will present at the UBS Global Healthcare Virtual Conference on May 26, 2021, at 12:00 p.m. Eastern Time. The presentation aims to showcase the company’s advancements in neurological therapies.
The session will be available to watch on-demand for 30 days on ClearPoint Neuro's website, specifically in the Investor Relations section. ClearPoint focuses on delivering therapies for complex neurological disorders using its Navigation System, which has over 4,500 successful procedures and partnerships with over 30 companies in the pharmaceutical and biotechnology sectors.
ClearPoint Neuro has announced the first human cases using its SmartFrame Array Neuro Navigation System, aiming to enhance neurosurgery workflows by reducing procedure times in MRI and Operating Room settings. The Array system's flexibility is expected to increase accessibility for hospitals and surgeons. Initial procedures were conducted by prominent neurosurgeons at renowned institutions, showcasing the system's efficiency. Full market release of the Array is anticipated in early 2022, following a phase of limited market release to gather training materials and case studies.
FAQ
What is the current stock price of Clearpoint Neuro (CLPT)?
What is the market cap of Clearpoint Neuro (CLPT)?
What does ClearPoint Neuro, Inc. do?
What is the ClearPoint® System?
Is the ClearTrace® System available?
What recent advancements has ClearPoint Neuro made?
What financial achievements did ClearPoint Neuro report in the fourth quarter of 2023?
What is the SmartFlow® Cannula used for?
How does ClearPoint Neuro contribute to gene and cell therapy?
Where can I find more information about ClearPoint Neuro?
How has ClearPoint Neuro's financial status improved recently?
What is the significance of the Prism Neuro Laser Therapy System?
